Claims
- 1. A compound of formula I
- 2. A compound of formula II
- 3. The compound of claim 2 of formula II
- 4. The compound of claim 2 of formula II
- 5. The compound of claim 2 of formula II
- 6. The compound of claim 5R1 is selected from the group consisting of: SO2R6, NR6R7, NR6SO2R7, and SO2N(R6)R7 wherein R6 and R7 may be taken together to form a 3-7 membered carbocyclic ring having 1 to 3 substituted or unsubstituted heteroatoms selected from the group consisting of: S, SO, SO2, O, and NR6; R2 is hydrido; R3 is selected from the group consisting of: CONHR7, NHCOR6, and CH2NHCOR6; R4 is selected from the group consisting of: halogen, alkylsulfinyl, alkylsulfonyl, cyano, alkoxycarbonyl, alkyl, haloalkyl, hydrido, hydroxyalkyl, haloalkoxy, heterocyclic, nitro, acylamino, aryl, heteroaryl, and alkenyl, OR13, SR8, SO2N(R8)R8′, NHR9, NHCOR9, NR9COR9, NHCO(OR9), NR9CO(OR9), NR8SO2R10, NHSO2N(R10)R10′, NR6CON(R10)R10′, COR9, CO2R8, CON(R8)R8′, wherein R8 and R8′ may be taken together to form a 3-7 membered carbocyclic ring having 1 to 3 substituted or unsubstituted heteroatoms selected from S, SO, SO2, O, N, and NR6, and wherein R10 and R10′ may be taken together to form a 3-7 membered carbocyclic ring having 1 to 3 substituted or unsubstituted heteroatoms selected from S, SO, SO2, O, N, and NR6 wherein said aryl, heterocyclic, heteroaryl, or alkenyl are optionally substituted with R9; R5 is selected from the group consisting of: hydrido, alkyl, aryl, arylalkyl, heteroaryl, heterocyclicalkyl, and heteroarylalkyl, wherein aryl, alkyl, arylalkyl, heteroaryl, heterocyclicalkyl, or heteroarylalkyl are optionally substituted with one or more radicals selected from the group consisting of OR14, N(R14)R14′, and glycols; R6 is independently selected from the group consisting of: hydrido, aryl, heteroaryl, lower alkyl, haloalkyl, alkenyl, alkynyl, hydroxyalkyl, aminoalkyl, alkylaminoalkyl, alkoxy, alkoxyalkyl, heterocyclicalkyl, and heterocyclic; R7 is independently selected from the group consisting of: hydrido, aryl, heteroaryl, lower alkyl, haloalkyl, alkenyl, alkynyl, hydroxyalkyl, aminoalkyl, alkylaminoalkyl, alkoxy, alkoxyalkyl, heterocyclicalkyl, and heterocyclic; R8 is independently selected from the group consisting of: hydrido, aryl, heteroaryl, arylalkyl, heterocyclic, haloalkyl, arylalkylamino, alkylaminoalkyl, dialkylaminoalkyl, alkyl, alkenyl, alkynyl, heteroarylalkyl, and heterocyclicalkyl; R8′ is independently selected from the group consisting of: hydrido, aryl, heteroaryl, arylalkyl, heterocyclic, haloalkyl, arylalkylamino, alkylaminoalkyl, dialkylaminoalkyl, alkyl, alkenyl, alkynyl, heteroarylalkyl, and heterocyclicalkyl; R9 is independently selected from the group consisting of: hydrido, lower alkyl, aryl, heteroaryl, arylalkyl, heterocyclic, cycloalkyl, heterocyclicalkyl, haloalkyl, arylalkylamino, amino, aminoalkyl, aminoacyl, nitro, azido, and heteroarylalkyl, wherein alkyl, aryl, heteroaryl, aminoalkyl, or arylalkyl are optionally substituted with one or more radical selected from the group consisting of: alkylsulfonamide, sulfamyl, alkyl, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, aminoalkyl, alkylaminoalkyl, alkoxy, halogen, acyloxy, oxy, formyl, haloalkyl, cyano, haloalkoxy, acyl, carboxyl, hydroxy, hydroxyalkyloxy, phenoxy, nitro, azido, benzyloxy, dialkylaminoacyl, thioalkyl, aminoacyloxy, thiocyanate, isothiocyanate, alkyldioxy, hydroxyalkyl, alkylamino, alkyloxycarbonyl, alkoxyalkyl, alkenylamino, alkynylamino, alkenyl, alkynyl, dialkylaminoalkyloxy, and heterocyclic optionally substituted with alkyl, alkylamino, aminoalkyl, and alkylaminoalkyl; R10 is independently selected from the group consisting of: hydrido, lower alkyl, heteroaryl, heterocyclic, haloalkyl, arylalkylamino, heteroarylalkyl, aryl, and arylalkyl, wherein aryl, heteroaryl, heterocyclic, or arylalkyl are optionally substituted with one or more radical selected from alkyl, alkoxy, halogen, haloalkyl, cyano, haloalkoxy, acyl, carboxyl, hydroxy, hydroxyalkyloxy, phenoxy, benzyloxy, dialkylaminoalkyloxy, and heterocyclic, R10′ is independently selected from the group consisting of: hydrido, lower alkyl, heteroaryl, heterocyclic, haloalkyl, arylalkylamino, heteroarylalkyl, aryl, and arylalkyl, wherein aryl, heteroaryl, heterocyclic, or arylalkyl are optionally substituted with one or more radical selected from alkyl, alkoxy, halogen, haloalkyl, cyano, haloalkoxy, acyl, carboxyl, hydroxy, hydroxyalkyloxy, phenoxy, benzyloxy, dialkylaminoalkyloxy, and heterocyclic, R11 is selected from the group consisting of: hydrido, halogen, haloalkyl, CN, CO2R5, lower alkyl, lower alkenyl, lower alkynyl, alkoxy, and CONH2; R12 is hydrido; R13 is selected from the group consisting of: hydrido, alkyl, aryl, arylalkyl, heteroaryl, heterocyclicalkyl, and heteroarylalkyl, wherein aryl, alkyl, arylalkyl, heteroaryl, heterocyclicalkyl, or heteroarylalkyl are optionally substituted with one or more radicals selected from the group consisting of OR14, N(R14)R14′, and glycols; R14 is independently selected from the group consisting of hydrido, and lower alkyl; and R14′ is independently selected from the group consisting of hydrido, and lower alkyl; or isomers, tautomers, carriers, esters, prodrugs, pharmaceutically acceptable salts thereof.
- 7. The compound of claim 6
- 8. The compound of claim 7 of the formula
- 9. The compound of claim 3 selected from the group consisting of:
1-[4-(aminosulfonyl)phenyl]-6-(4-methoxyphenyl)-1H-indazole-3-carboxamide, 1-[4-(aminosulfonyl)phenyl]-6-(4-fluorophenyl)-1H-indazole-3-carboxamide, 1-[4-(aminosulfonyl)phenyl]-6-(3-methylphenyl)-1H-indazole-3-carboxamide, 1-[4-(aminosulfonyl)phenyl]-6-(4-tert-butylphenyl)1-H-indazole-3-carboxamide, 1-[4-(aminosulfonyl)phenyl]-6-(4-fluoro-3-methylphenyl)-1H-indazole-3-carboxamide, 1-[4-(aminosulfonyl)phenyl]-6-[3-(dimethylamino)phenyl]-1H-indazole-3-carboxamide, 1-[4-(aminosulfonyl)phenyl]-6-[3-(methylamino)phenyl]-1H-indazole-3-carboxamide, 1-[4-(aminosulfonyl)phenyl]-1H-pyrazolo[4,3-c]pyridine-3-carboxamide, 1-[4-(aminosulfonyl)phenyl]-6-methyl-1H-indazole-3-carboxamide, 1-[4-(aminosulfonyl)phenyl]-6-phenyl-1H-indazole-3-carboxamide, 1-[4-(aminosulfonyl)phenyl]-6-(3-methoxyphenyl)-1H-indazole-3-carboxamide, 1-[4-(aminosulfonyl)phenyl]-6-benzyl-1H-indazole-3-carboxamide, 1-[4-(aminosulfonyl)phenyl]-6-ethoxy-1H-indazole-3-carboxamide, 1-[4-(aminosulfonyl)phenyl]-6-ethyl-1H-indazole-3-carboxamide, 1-[4-(aminosulfonyl)phenyl]-6-pyridin-3-yl-1H-indazole-3-carboxamide, 1-[4-(aminosulfonyl)phenyl]-6-(2-hydroxyphenyl)-1H-indazole-3-carboxamide, 1-[4-(aminosulfonyl)phenyl]-6-(3-hydroxyphenyl)-1H-indazole-3-carboxamide, 6-(2-hydroxyphenyl)-1-[4-(methylsulfonyl)phenyl]-1H-indazole-3-carboxamide, and 1-[3-(aminosulfonyl)phenyl]-6-phenyl-1H-indazole-3-carboxamide.
- 10. The compound of claim 6 of the formula
- 11. The compound of claim 6 of the formula
- 12. A composition comprising the compound of claim 1 or 2, and at least one pharmaceutically acceptable carrier.
- 13. A method of treating cancer, inflammation or an inflammation associated disorder in a subject, said method comprising administering to the subject having or susceptible to such cancer, inflammation or inflammation associated disorder, a therapeutically-effective amount of a compound of claim 1, or 2.
- 14. The method of claim 11 for use in the treatment of cancer.
- 15. The method of claim 11 for use in the treatment of inflammation.
- 16. The method of claim 11 for use in the treatment of an inflammation-associated disorder.
- 17. The method of claim 14 wherein the inflammation-associated disorder is arthritis.
- 18. The method of claim 14 wherein the inflammation-associated disorder is pain
- 19. The method of claim 14 wherein the inflammation-associated disorder is fever.
Government Interests
[0001] The present application claims priority under Title 35, United States Code, §119 to U.S. Provisional application Serial No. 60/323,424, filed Sep. 19, 2001, which is incorporated by reference in its entirety as if written herein.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60323424 |
Sep 2001 |
US |